Lilly Suzhou Pharmaceutical Expands Insulin Plant
This article was originally published in PharmAsia News
Executive Summary
Lilly Suzhou Pharmaceutical recently held a ground-breaking ceremony for its Suzhou plant expansion project. With an investment of more than $40 million, the plant will cover an area of 50,000 square meters, 60 percent bigger than the current factory, and will be used mainly for packaging and storing insulin products. After completion of the project, both the existing and new plants will produce insulin products. The new plant will help Lilly increase its insulin production capacity to meet China's growing pharmaceutical market needs. (Click here for more - Chinese Language)
You may also be interested in...
Display Of IP Strength In China: Lilly Wins Patent Dispute For Cialis Against Domestic Chinese Company
SHANGHAI - Eli Lilly's win of the patent infringement suit in China against Jiangyin Dongfang Pharmaceutical for manufacturing tadalafil, the active ingredient in Lilly's male erectile dysfunction drug Cialis, is good news for multinational companies operating in China
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.